BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 905 filers reported holding BAXTER INTL INC in Q4 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $560 | -9.7% | 16,752 | +15.6% | 0.01% | -12.5% |
| Q1 2024 | $620 | +36.6% | 14,496 | +23.4% | 0.01% | +33.3% |
| Q4 2023 | $454 | +10.7% | 11,748 | +8.2% | 0.01% | 0.0% |
| Q3 2023 | $410 | -99.9% | 10,857 | +107.0% | 0.01% | -66.7% |
| Q4 2019 | $439,000 | -9.9% | 5,246 | -5.7% | 0.02% | -21.7% |
| Q3 2019 | $487,000 | +1.9% | 5,566 | -4.7% | 0.02% | -56.6% |
| Q2 2019 | $478,000 | +8.1% | 5,839 | +7.9% | 0.05% | +120.8% |
| Q1 2019 | $442,000 | +33.9% | 5,410 | -3.4% | 0.02% | -33.3% |
| Q2 2017 | $330,000 | – | 5,603 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
| NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
| Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
| Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
| GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
| Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
| Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
| Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
| Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |